Floatz logo

Sirolimus

Prolymphocytic Leukemia

Explore 21 assets in Prolymphocytic Leukemia →
Floatz Rating
B61/100
Confidence
Indicative
v0.2
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05805605CT.gov
Allo HSCT Using RIC and PTCy for Hematological Diseases
—Recruiting———
NCT03246906CT.gov
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
—Terminated———
NCT02722668CT.gov
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
—Completed———
NCT01251575CT.gov
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
—Completed———
NCT01231412CT.gov
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Prolymphocytic Leukemia

AssetSponsorPhaseRating
Sirolimus (this asset)Masonic Cancer Center, University of MinnesotaP3B · 61
CyclophosphamideCenter for International Blood and Marrow Transplant ResearchP2BBB
FludarabineCenter for International Blood and Marrow Transplant ResearchP3BB
NivestimCenter for International Blood and Marrow Transplant ResearchP2BB
Cyclosporin AFred Hutchinson Cancer CenterP3BB
TacrolimusCenter for International Blood and Marrow Transplant ResearchP2BB
BusulfanumCenter for International Blood and Marrow Transplant ResearchP2BB
MelphalanCenter for International Blood and Marrow Transplant ResearchP2BB
IbrutinibFred Hutchinson Cancer CenterP2B

+42 more in the Prolymphocytic Leukemia cohort

Other indications for Sirolimus

IndicationSponsorPhaseRating
Tuberous Sclerosis—P3BBB · 73
Disease Related To Transplantation—P4BBB · 72
Myelodysplastic/Myeloproliferative Neoplasm—P2BB · 69

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Sirolimus in Prolymphocytic Leukemia. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/sirolimus-prolymphocytic-leukemia

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →